RecruitingGastroesophageal-junction CancerMonoclonal AntibodyGastric Cancer

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Eligible age

18+ yrs

Accepts

All genders

Locations

14 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a double-blind, randomized, multiregion, comparative phase Ⅲ clinical study designed to evaluate the efficacy and safety of HLX22 in combination with trastuzumab and chemotherapy as first-line treatment in patients with HER2-positive locally advanced/metastatic adenocarcinoma of the gastric and/or gastroesophageal junction (G/GEJ).Eligible subjects will be randomized to the two groups based on a 1:1 ratio. Enrolled subjects shall be treated with the study drug until the loss of clinical benefit, death, intolerable toxicity, withdrawal of informed consent, or other reasons specified by the protocol (whichever occurs first).

Sponsor: Shanghai Henlius Biotech

You may qualify if…

✓ 1. Male/female who are at least 18 years of age on the day of signing the informed consent.
✓ 2. With histologically or cytologically confirmed diagnosis of previously untreated, locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.
✓ 3. Had measurable disease as assessed by IRRC according to the RECIST v1.1, the target lesion must not be a bone metastatic lesion only.
✓ 4. HER2-positive tumor defined as either IHC 3+ or IHC 2+ in combination with ISH+ or FISH, as assessed by a central laboratory on a primary or metastatic tumor.
✓ 5. ECOG PS within 7 days before randomization: 0-1.
✓ 6. Expected survival ≥ 6 months.
✓ 7. Had adequate organ function

You may not qualify if…

✕ 1. Patients with other malignant tumors within 2 years before the randomization.
✕ 2. Evidence of disease progression within 6 months (before randomization) after completion of prior neoadjuvant or adjuvant chemotherapy (or both) or radiotherapy for gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.
✕ 3. Previous treatment with any HER2-target therapy.
✕ 4. Active gastrointestinal bleeding
✕ 5. Presence of central nervous system (CNS) metastases.
✕ 6. Left ventricular ejection fraction (LVEF) \< 55%.
✕ 7. Subjects who had known history of severe allergy to any monoclonal antibody or any component of study treatment.